

Product datasheet for **TL313443V**

Dystrophin (DMD) Human shRNA Lentiviral Particle (Locus ID 1756)

Product data:

| | |
|---------------|---|
| Product Type: | shRNA Lentiviral Particles |
| Product Name: | Dystrophin (DMD) Human shRNA Lentiviral Particle (Locus ID 1756) |
| Locus ID: | 1756 |
| Synonyms: | BMD; CMD3B; DXS142; DXS164; DXS206; DXS230; DXS239; DXS268; DXS269; DXS270; DXS272; MRX85 |
| Vector: | pGFP-C-shLenti (TR30023) |
| Format: | Lentiviral particles |
| Components: | DMD - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml. |
| RefSeq: | NM_000109 , NM_004006 , NM_004007 , NM_004009 , NM_004010 , NM_004011 , NM_004012 , NM_004013 , NM_004014 , NM_004015 , NM_004016 , NM_004017 , NM_004018 , NM_004019 , NM_004020 , NM_004021 , NM_004022 , NM_004023 , NM_004023.1 , NM_004023.2 , NM_004013.1 , NM_004013.2 , NM_004021.1 , NM_004021.2 , NM_004009.1 , NM_004009.2 , NM_004009.3 , NM_004019.1 , NM_004019.2 , NM_004018.1 , NM_004018.2 , NM_004006.1 , NM_004006.2 , NM_004011.1 , NM_004011.2 , NM_004011.3 , NM_004010.1 , NM_004010.2 , NM_004010.3 , NM_004007.1 , NM_004007.2 , NM_004012.1 , NM_004012.2 , NM_004012.3 , NM_004016.1 , NM_004016.2 , NM_000109.1 , NM_000109.2 , NM_000109.3 , NM_004014.1 , NM_004014.2 , NM_004017.1 , NM_004017.2 , NM_004020.1 , NM_004020.2 , NM_004020.3 , NM_004022.1 , NM_004022.2 , NM_004015.1 , NM_004015.2 , BC009242 , BC010932 , BC028720 , BC036103 , BC070078 , BC094758 , BC111587 , BC111836 , BC111934 , BC118002 , BC127103 , BC150141 , NM_004016.3 , NM_004017.3 , NM_004019.3 , NM_004018.3 , NM_004015.3 |
| UniProt ID: | P11532 |
| Summary: | This gene spans a genomic range of greater than 2 Mb and encodes a large protein containing an N-terminal actin-binding domain and multiple spectrin repeats. The encoded protein forms a component of the dystrophin-glycoprotein complex (DGC), which bridges the inner cytoskeleton and the extracellular matrix. Deletions, duplications, and point mutations at this gene locus may cause Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or cardiomyopathy. Alternative promoter usage and alternative splicing result in numerous distinct transcript variants and protein isoforms for this gene. [provided by RefSeq, Dec 2016] |



[View online »](#)

shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our [custom shRNA service](#).

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).